Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
|
| gptkbp:activeIngredient |
gptkb:oxycodone
|
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II_(US)
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:form |
immediate-release tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
OxyIR
|
| gptkbp:manufacturer |
gptkb:Mallinckrodt_Pharmaceuticals
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:riskFactor |
addiction
respiratory depression |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
constipation drowsiness |
| gptkbp:usedFor |
pain management
|
| gptkbp:bfsParent |
gptkb:Purdue_Pharma
|
| gptkbp:bfsLayer |
6
|